ALKERMES | ALKS - Assets


ALKERMES reported $4.39B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
J&J USD 197.42B 3.64B Sep/2026
Malin Corporation EUR 198.5M 70.1M Dec/2024
Merck USD 129.8B 1.12B Jun/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Otsuka Holdings JPY 4.4T 186.7B Jun/2026
Ovoca Bio EUR 2.07M 414K Dec/2025
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026